Omics and drug response.

A new generation of technologies commonly named omics permits assessment of the entirety of the components of biological systems and produces an explosion of data and a major shift in our concepts of disease. These technologies will likely shape the future of health care. One aspect of these advances is that the data generated document the uniqueness of each human being in regard to disease risk and treatment response. These developments have reemphasized the concept of personalized medicine. Here we review the impact of omics technologies on one key aspect of personalized medicine: the individual drug response. We describe how knowledge of different omics may affect treatment decisions, namely drug choice and drug dose, and how it can be used to improve clinical outcomes.

[1]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[2]  Shih-Chieh Chang,et al.  Images in clinical medicine. Acute mesenteric infarction associated with atrial fibrillation. , 2011, The New England journal of medicine.

[3]  R. Aebersold,et al.  Advancing Cell Biology Through Proteomics in Space and Time (PROSPECTS)* , 2012, Molecular & Cellular Proteomics.

[4]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[5]  S. Willmann,et al.  Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.

[6]  C. Day,et al.  Genetic association studies in drug-induced liver injury , 2012, Drug metabolism reviews.

[7]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[8]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[9]  M. Dolan,et al.  The emerging role of microRNAs in drug responses. , 2010, Current opinion in molecular therapeutics.

[10]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[11]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[12]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[13]  P. Visscher,et al.  Five years of GWAS discovery. , 2012, American journal of human genetics.

[14]  M. Mann,et al.  Quantitative, high-resolution proteomics for data-driven systems biology. , 2011, Annual review of biochemistry.

[15]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[16]  Omar E. Cornejo,et al.  Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence , 2011, PLoS genetics.

[17]  J. Croxtall,et al.  Fulvestrant , 2011, Drugs.

[18]  I. Thethi,et al.  Old versus new oral anticoagulants: focus on pharmacology. , 2012, Annual review of pharmacology and toxicology.

[19]  Jacek Majewski,et al.  The study of eQTL variations by RNA-seq: from SNPs to phenotypes. , 2011, Trends in genetics : TIG.

[20]  Jun Wu,et al.  Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL- VP16 and the two nonacidic activation functions of the estrogen receptor , 1993, Nucleic Acids Res..

[21]  A. Daly,et al.  Pharmacogenetics and human genetic polymorphisms. , 2010, The Biochemical journal.

[22]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[23]  Magnus Ingelman-Sundberg,et al.  Pharmacogenomic biomarkers: new tools in current and future drug therapy. , 2011, Trends in pharmacological sciences.

[24]  E. Deeks,et al.  Exemestane , 2012, Drugs.

[25]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[26]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[27]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[28]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[29]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[30]  S. Rappaport.  Implications of the exposome for exposure science , 2011, Journal of Exposure Science and Environmental Epidemiology.

[31]  E. Lander,et al.  The mystery of missing heritability: Genetic interactions create phantom heritability , 2012, Proceedings of the National Academy of Sciences.

[32]  J. Gray,et al.  Omics and therapy – A basis for precision medicine , 2012, Molecular oncology.

[33]  D M Roden,et al.  Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges , 2012, Clinical pharmacology and therapeutics.

[34]  Christian Gieger,et al.  A genome-wide association study of metabolic traits in human urine , 2011, Nature Genetics.

[35]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[36]  Lincoln Stein,et al.  The SNP Consortium website: past, present and future , 2003, Nucleic Acids Res..

[37]  J. Blay,et al.  Nilotinib: a novel, selective tyrosine kinase inhibitor. , 2011, Seminars in oncology.

[38]  Fernando Rivadeneira,et al.  A genome-wide association study of acenocoumarol maintenance dosage. , 2009, Human molecular genetics.

[39]  Cheng Cheng,et al.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Lindon,et al.  Systems biology: Metabonomics , 2008, Nature.

[41]  J. Tabernero,et al.  Panitumumab: a summary of clinical development in colorectal cancer and future directions. , 2012, Future oncology.

[42]  S. Keam,et al.  Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. , 2011, Drugs.

[43]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[44]  J. Kelsoe,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.

[45]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[46]  S. Mallal,et al.  Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.

[47]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[48]  S. Hanash.  Building a foundation for the human proteome: the role of the Human Proteome Organization. , 2004, Journal of proteome research.

[49]  D. Balding,et al.  Epigenome-wide association studies for common human diseases , 2011, Nature Reviews Genetics.

[50]  C. Garrett,et al.  Cetuximab in the treatment of patients with colorectal cancer , 2011, Expert opinion on biological therapy.

[51]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[52]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[53]  J. Mendell,et al.  MicroRNAs in Stress Signaling and Human Disease , 2012, Cell.

[54]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[55]  C. Gieger,et al.  Human metabolic individuality in biomedical and pharmaceutical research , 2011, Nature.

[56]  M. Pirmohamed.  Pharmacogenetics: past, present and future. , 2011, Drug discovery today.

[57]  Melissa A. Basford,et al.  Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. , 2012, Pharmacogenomics.

[58]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[59]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[60]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[61]  Melissa A. Basford,et al.  Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. , 2010, American journal of human genetics.

[62]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[64]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[65]  Yusuke Nakamura,et al.  A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese , 2022 .

[66]  D. Schaid,et al.  Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics‐Informed Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.

[67]  A Floratos,et al.  Genome-wide association study of serious blistering skin rash caused by drugs , 2011, The Pharmacogenomics Journal.

[68]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[69]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[70]  Ross J Molinaro,et al.  Cancer biomarkers: surviving the journey from bench to bedside. , 2011, MLO: medical laboratory observer.

[71]  B. Horne,et al.  A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) , 2012, Circulation.

[72]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[73]  Ruedi Aebersold,et al.  Options and considerations when selecting a quantitative proteomics strategy , 2010, Nature Biotechnology.

[74]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .

[75]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[76]  U A Meyer,et al.  Personalized Medicine: A Personal View , 2012, Clinical pharmacology and therapeutics.

[77]  Shiew-Mei Huang,et al.  A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity , 2009, Journal of clinical pharmacology.

[78]  Teri A Manolio,et al.  Genomewide association studies and assessment of the risk of disease. , 2010, The New England journal of medicine.

[79]  F. Wright,et al.  Use of Pharmaco‐Metabonomics for Early Prediction of Acetaminophen‐Induced Hepatotoxicity in Humans , 2010, Clinical pharmacology and therapeutics.

[80]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[81]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[82]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[83]  E. Mardis.  The $1,000 genome, the $100,000 analysis? , 2010, Genome Medicine.

[84]  C. Perry.  Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. , 2010, Drugs.

[85]  Joseph K. Pickrell,et al.  A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.

[86]  R. Aebersold,et al.  Mass spectrometry-based proteomics and network biology. , 2012, Annual review of biochemistry.

[87]  B. Druker.  Circumventing resistance to kinase-inhibitor therapy. , 2006, The New England journal of medicine.

[88]  M. Curran.  Crizotinib: in locally advanced or metastatic non-small cell lung cancer. , 2012, Drugs.

[89]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[90]  S. Mallal,et al.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  I. Yang,et al.  Molecular staging for survival prediction of colorectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  M. J. van de Vijver,et al.  The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[94]  Julia E. Vogt,et al.  Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. , 2011, Gastroenterology.

[95]  Caroline H. Johnson,et al.  Challenges and opportunities of metabolomics , 2012, Journal of cellular physiology.

[96]  A. Henney,et al.  The virtual liver: a multidisciplinary, multilevel challenge for systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[97]  Mitchell R. McGill,et al.  Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. , 2012, Journal of hepatology.

[98]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[99]  Ryan M. Smith,et al.  mRNA Transcript Diversity Creates New Opportunities for Pharmacological Intervention , 2012, Molecular Pharmacology.

[100]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[101]  M. Esteller,et al.  Cancer epigenomics: beyond genomics. , 2012, Current opinion in genetics & development.

[102]  A. Daly,et al.  Genome-wide association studies in pharmacogenomics , 2010, Nature Reviews Genetics.

[103]  Peter Donnelly,et al.  Edinburgh Research Explorer Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2022 .

[104]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[105]  D. Galas,et al.  Diseases as network perturbations. , 2010, Current opinion in biotechnology.

[106]  D. Banerjee,et al.  A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance , 2007, Proceedings of the National Academy of Sciences.

[107]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[108]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[109]  J. Lindon,et al.  Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. , 2008, Annual review of analytical chemistry.

[110]  G. Rosner,et al.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. , 2012, Genome research.

[111]  T. Spector,et al.  Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[113]  Russ Altman,et al.  Pharmacogenomics: Challenges and Opportunities , 2006, Annals of Internal Medicine.

[114]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[115]  Y-L Chung,et al.  Using metabolomics to monitor anticancer drugs. , 2007, Ernst Schering Foundation symposium proceedings.

[116]  Jung A Kim.  The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care , 2011 .

[117]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.

[118]  S. Scott,et al.  Personalizing medicine with clinical pharmacogenetics , 2011, Genetics in Medicine.

[119]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[120]  D. Slamon,et al.  Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy , 2004, Breast Cancer Research and Treatment.

[121]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[122]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[123]  Jerry L. Campbell,et al.  Evaluating Pharmacokinetic and Pharmacodynamic Interactions with Computational Models in Supporting Cumulative Risk Assessment , 2011, International journal of environmental research and public health.

[124]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[125]  Noam Shomron,et al.  MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. , 2011, Trends in molecular medicine.

[126]  A. Chinnaiyan,et al.  Integrative analysis of the cancer transcriptome , 2005, Nature Genetics.

[127]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[128]  B. Druker.  Perspectives on the development of imatinib and the future of cancer research , 2009, Nature Medicine.

[129]  Stephen E Kimmel,et al.  Genetic warfarin dosing: tables versus algorithms. , 2011, Journal of the American College of Cardiology.

[130]  D. Roden,et al.  Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. , 2011, Blood.

[131]  F. Collins,et al.  Genomic medicine--an updated primer. , 2010, The New England journal of medicine.

[132]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[133]  S. Omholt,et al.  Phenomics: the next challenge , 2010, Nature Reviews Genetics.

[134]  Andrew D. Johnson,et al.  Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy , 2011, Clinical pharmacology and therapeutics.

[135]  D. Roden,et al.  Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record , 2012, Clinical pharmacology and therapeutics.

[136]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[137]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[138]  A. Shuldiner,et al.  Pharmacogenomics: Application to the Management of Cardiovascular Disease , 2011, Clinical pharmacology and therapeutics.

[139]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[140]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[141]  M. Ingelman-Sundberg,et al.  Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.

[142]  V. Jordan,et al.  Tamoxifen: catalyst for the change to targeted therapy. , 2008, European journal of cancer.

[143]  M. Cronin,et al.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. , 2007, Clinical chemistry.

[144]  Ute Hofmann,et al.  DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma , 2011, Genome Medicine.

[145]  John P A Ioannidis,et al.  Clinical outcome prediction by microRNAs in human cancer: a systematic review. , 2012, Journal of the National Cancer Institute.

[146]  Á. Rodríguez-Lescure,et al.  An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer , 2011, Advances in therapy.

[147]  Soma Das,et al.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  A. Daly.  Using genome-wide association studies to identify genes important in serious adverse drug reactions. , 2012, Annual review of pharmacology and toxicology.

[149]  M. Rieder,et al.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.

[150]  O. Abdel-Wahab,et al.  A novel tumor suppressor function for the Notch pathway in myeloid leukemia , 2011, Nature.

[151]  A. Skol,et al.  The limits of genome-wide methods for pharmacogenomic testing , 2012, Pharmacogenetics & Genomics.

[152]  R. Verbrugge,et al.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). , 2010, Journal of the American College of Cardiology.

[153]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[154]  K. Burrage,et al.  The Systems Biology Approach to Drug Development: Application to Toxicity Assessment of Cardiac Drugs , 2010, Clinical pharmacology and therapeutics.

[155]  Fatih Ozsolak,et al.  RNA sequencing: advances, challenges and opportunities , 2011, Nature Reviews Genetics.

[156]  Judy Illes,et al.  Personal medicine—the new banking crisis , 2012, Nature Biotechnology.

[157]  J. Lindon,et al.  Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy , 2012, Expert opinion on drug metabolism & toxicology.

[158]  A. Hofman,et al.  Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes , 2011, Pharmacogenetics and genomics.

[159]  Urs A. Meyer,et al.  Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.

[160]  Guey-Shin Wang,et al.  Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.

[161]  I. Koturbash,et al.  Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants , 2012, Expert opinion on drug metabolism & toxicology.

[162]  Muin J Khoury,et al.  Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time , 2011, Genetics in Medicine.

[163]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[164]  Hsien-Da Huang,et al.  microRNA: a master regulator of cellular processes for bioengineering systems. , 2010, Annual review of biomedical engineering.

[165]  S. Brunak,et al.  Mining electronic health records: towards better research applications and clinical care , 2012, Nature Reviews Genetics.

[166]  Russ B Altman,et al.  PharmGKB summary: very important pharmacogene information for G6PD , 2012, Pharmacogenetics and genomics.

[167]  C. Richards,et al.  Emergency Hospitalization for Adverse Drug Events in Older Americans , 2012 .

[168]  P. Workman,et al.  Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. , 2012, Annual review of pharmacology and toxicology.

[169]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[170]  John R Yates,et al.  Proteomics by mass spectrometry: approaches, advances, and applications. , 2009, Annual review of biomedical engineering.

[171]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[172]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[173]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.

[174]  R. Guigó,et al.  Transcriptome genetics using second generation sequencing in a Caucasian population , 2010, Nature.

[175]  Anne-Mette K. Hein,et al.  Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study , 2007, Clinical Cancer Research.

[176]  R. Figlin,et al.  Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape , 2010, Molecular Cancer Therapeutics.

[177]  J. Lupski,et al.  Human genome sequencing in health and disease. , 2012, Annual review of medicine.

[178]  Denis Noble,et al.  The Cardiac Physiome: perspectives for the future , 2009, Experimental physiology.

[179]  B. Solomon,et al.  Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer , 2012, Journal of personalized medicine.

[180]  P. Watkins,et al.  The Application of Metabonomics to Predict Drug‐Induced Liver Injury , 2010, Clinical pharmacology and therapeutics.

[181]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[182]  Alfio Quarteroni,et al.  A vision and strategy for the virtual physiological human in 2010 and beyond , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[183]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[184]  Giovanni Parmigiani,et al.  The Predictive Capacity of Personal Genome Sequencing , 2012, Science Translational Medicine.

[185]  Markus Perola,et al.  Metabonomic, transcriptomic, and genomic variation of a population cohort , 2010, Molecular systems biology.

[186]  T. Klein,et al.  Clopidogrel: A Case for Indication‐Specific Pharmacogenetics , 2012, Clinical pharmacology and therapeutics.

[187]  E. Dermitzakis,et al.  Rare and Common Regulatory Variation in Population-Scale Sequenced Human Genomes , 2011, PLoS genetics.

[188]  Stephen A Ramsey,et al.  A systems biology approach to understanding atherosclerosis , 2010, EMBO molecular medicine.

[189]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[190]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[191]  D. Roden,et al.  Genetic determinants of response to cardiovascular drugs , 2012, Current opinion in cardiology.